Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

NCT02065869 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

187

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Acute Lymphoblastic Leukemia
Leukemia, Acute Myeloid (AML), Child
Lymphoma, Non-Hodgkin
Myelodysplastic Syndrome
Primary Immunodeficiency
Anemia, Aplastic
Osteopetrosis
Hemoglobinopathies
Cytopenia
Fanconi Anemia
Diamond Blackfan Anemia
Thalassemia
Anemia, Sickle Cell

Interventions

BIOLOGICAL: BPX-501 T cells
DRUG: Rimiducid

Sponsor

Bellicum Pharmaceuticals